Real-World Treatment Discontinuation of Risankizumab Versus IL-17 Inhibitors in Japanese Patients With Psoriatic Arthritis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1327; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • HEOR • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A
|